Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin |
| Type de publication | Journal Article |
| Year of Publication | 2021 |
| Auteurs | Zaanan A, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, Lecomte T, Aparicio T, Svrcek M, Taieb J, Andre T, Vernerey D, Tougeron D, Oncologu AGastro-ent |
| Journal | JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE |
| Volume | 113 |
| Pagination | djaa072 |
| Date Published | APR |
| Type of Article | Article |
| ISSN | 0027-8874 |
| Résumé | {Anti-epidermal growth factor receptor (EGFR) efficacy in patients with microsatellite instability (MSI) metastatic colorectal cancer (mCRC) according to sporadic vs familial origin is unknown. We retrospectively analyzed 128 patients with MSI mCRC treated with first-line chemotherapy +/- anti-EGFR. Among them, 61 and 67 patients were respectively categorized as familial and sporadic based on mismatch repair protein immunostaining, BRAF mutational status, and MLH1 promoter methylation status. We observed that addition of anti-EGFR to chemotherapy was associated with a statistically significant improvement of progression-free survival for familial (median = 5.0 vs 10.2 months, hazard ratio [HR] = 0.47, 95% confidence interval [CI] = 0.23 to 0.94; P = .03) but not for sporadic (median = 4.4 vs 5.4 months |
| DOI | 10.1093/jnci/djaa072 |